Management Team

Øystein Soug
Øystein Soug
Chief Executive Officer
Close
Øystein Soug
Øystein Soug
Chief Executive Officer

20 years in international banking and industry; previous CFO of Algeta ASA.

Øystein Soug has experience from 20 years in international banking industry and biotech. The last six years before joining the Company he was CFO of Algeta ASA, which developed and launched Xofigo and was sold for USD 2.9 billion to Bayer. Before his current CEO role, he was CFO of Targovax from May 2015 to October 2016. Prior to biotech, Mr. Soug held several CFO and business development positions with the Orkla Group and the European Bank for Reconstruction and Development (EBRD) in Norway and Russia. Oystein is an economist by training from the University of St. Gallen (lic.oec.HSG). Mr. Soug is a Norwegian citizen and resides in Norway.

Shares 190,000
Share options 1,160,000

 

Torbjørn Furuseth
Torbjørn Furuseth
Chief Financial Officer
Close
Torbjørn Furuseth
Torbjørn Furuseth
Chief Financial Officer

Experienced life science executive and medical doctor with background from McKinsey & Company.

Torbjørn Furuseth, an experienced executive with a broad background within life science. joined Targovax in September 2018. He has practiced as a physician and transitioned into business and management through six years as a management consultant at McKinsey & Company, where he served several pharma and healthcare clients. After McKinsey he joined pharma companies in the Norwegian industrial company Aker and eventually became EVP Innovation at Aker BioMarine, where he established and led the innovation department. His last position prior prior to Targovax as as CFO in Lytix Biopharma AS where he conducted several financing rounds. Torbjørn is a Medical Doctor from Norwegian University of Science and Technology (NTNU). Dr. Furuseth is a Norwegian citizen and resides in Norway.

Shares 0
Share options 300,000

 

Ingunn Munch Lindvig
Ingunn Munch Lindvig
VP, Regulatory Affairs
Close
Ingunn Munch Lindvig
Ingunn Munch Lindvig
VP, Regulatory Affairs

Extensive experience with regulatory strategy and more than 20 years in the pharma and biotech industry

Ingunn Munch Lindvig has more than 20 years in the pharma and biotech industry. She has extensive experience with regulatory strategy and delivery on regulatory plans across a range of pharmaceutical products. Prior to joining Targovax Dr. Lindvig was Head of Regulatory Affairs at Nordic Nanovector ASA for five years and she also led the regulatory function at Photocure ASA for seven years. Dr. Lindvig was part of the Regulatory team at Nycomed Imaging/Nycomed Amersham/GE Healthcare.

Dr. Lindvig holds a PhD in physiology from University of Oslo, Norway.  She is a Norwegian citizen and resides in Norway.

 

Shares
Share options

 

Sissel Vågen
Sissel Vågen
Head of QA
Close
Sissel Vågen
Sissel Vågen
Head of QA

18 years of experience within research & development and operation in the pharmaceutical and biotech industry

Sissel Vågen has 18 years of experience within research & development and operation in the pharmaceutical and biotech industry, including CMC, stability design, change control and quality assurance from preclinical product development through to regulatory approval and launch of products. She has held different positions within Technology Development Nycomed/GE-Healthcare and before joining Targovax Ms. Vågen worked in Quality Affairs in Pronova BioPharma. She holds a MSc degree in pharmacy from the University of Oslo. She is a Norwegian citizen and resides in Norway.

Shares
Share options

 

Kristiina Hyvärinen
Kristiina Hyvärinen
Director, CMC
Close
Kristiina Hyvärinen
Kristiina Hyvärinen
Director, CMC

More than 20 years of experience in research, biopharmaceutical and food supplement industry

Kristiina Hyvärinen has more than 20 years of experience in research, biopharmaceutical and food supplement industry. Before joining Targovax, Dr. Hyvärinen worked for seven years as Quality manager in Pharmia Oy where she was responsible of all quality aspects of the factory manufacturing vitamins and other food supplements as well as medical devices. Dr. Hyvärinen also worked for eight years in several positions including R&D scientist, chemist and QC laboratory manager at Ipsat Therapies Oy. She studied organic, analytical and biochemistry at the University of Helsinki, where she has also worked as research scientist.  Dr. Hyvärinen holds a PhD in chemistry from the University of Helsinki. She is Finnish citizen and resides in Helsinki, Finland.

Shares
Share options

 

Anne-Sophie W. Møller
Anne-Sophie W. Møller
Head of Clinical Science
Close
Anne-Sophie W. Møller
Anne-Sophie W. Møller
Head of Clinical Science

More than 15 years of experience within research and development, as well as operation from both academia and biotech industry within immunology and cell biology

Anne-Sophie W. Møller joined Targovax in August 2016. and has more than 15 years of experience within research and development as well as operation from both academia and biotech industry within immunology and cell biology. Dr. Møller worked as scientist for several years at Oslo University Hospital and held different managing positions in R&D, method development and quality control in Thermo Fisher.

She is currently Head of Clinical Science and is responsible for the immune monitoring program as well as the pre-clinical program in Targovax.

Dr. Møller holds a PhD in cell biology/Immunology from the University of Norway.  She is a Danish citizen and resides in Norway.

 

Shares
Share options

 

Magnus Jäderberg
Magnus Jäderberg
Chief Medical Officer
Close
Magnus Jäderberg
Magnus Jäderberg
Chief Medical Officer

A pharmaceutical physician with more than 30 years in various R&D functions and general management.

Magnus Jäderberg is a pharmaceutical physician with experience from more than 30 years in various R&D functions including clinical research, medical affairs, pharmacovigilance, strategic product development and general management. He is experienced in all phases of clinical research, including clinical pharmacology, dose finding, registration, post-launch product differentiation and pharmacovigilance. Dr. Jäderberg’s worked on the late stage development, registration and launch of Rapamune (sirolimus) and Yervoy (ipilimumab). Prior to joining Targovax, he held roles at national, European and global level at GSK, Pharmacia, Wyeth and most recently as Chief Medical Officer of Bristol Myers Squibb (Europe). Dr. Jaderberg qualified in medicine at Karolinska Institute, Stockholm, Sweden, and is a fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom. He is a Swedish citizen and resides in the United Kingdom.

Shares 20,000
Share options 840,000

 

Erik Digman Wiklund
Erik Digman Wiklund
Chief Business Officer
Close
Erik Digman Wiklund
Erik Digman Wiklund
Chief Business Officer

Former consultant in the Pharma & Healthcare practice of McKinsey & Company, combined with a PhD in cancer research.

Erik Digman Wiklund was hired as the Company’s CFO in April 2017. In order to better leverage his scientific expertise, he transitioned into the CBO role in October 2018. Dr. Wiklund previously worked for the Norwegian cancer biotechnology company Algeta ASA and the nutraceutical company Aker Biomarine Antarctic AS, where he held the position as Director of Product Innovation. He also has management consulting experience from the Pharma & Health Care practice of McKinsey & Company. Dr. Wiklund holds a PhD in Molecular Biology from Aarhus University, Denmark, and the Garvan Institute of Medical Research in Sydney, Australia. Dr. Wiklund is a Swedish citizen, residing in Norway.

Shares 0
Share options 430,000